Proof-of-Concept Randomized Trial of the Monoclonal Antibody GSK249320 Versus Placebo in Stroke Patients

@article{Cramer2017ProofofConceptRT,
  title={Proof-of-Concept Randomized Trial of the Monoclonal Antibody GSK249320 Versus Placebo in Stroke Patients},
  author={Steven C. Cramer and Lori A. Enney and Colleen K. Russell and Monica Simeoni and Thomas R. Thompson},
  journal={Stroke},
  year={2017},
  volume={48},
  pages={692 - 698}
}
Background and Purpose— One class of poststroke restorative therapy focuses on promoting axon outgrowth by blocking myelin-based inhibitory proteins such as myelin-associated glycoprotein. The purpose of the current study was to extend preclinical and clinical findings of GSK249320, a humanized monoclonal antibody to myelin-associated glycoprotein with disabled Fc region, to explore effects on motor outcomes poststroke. Methods— In this phase IIb double-blind, randomized, placebo-controlled… Expand
Recovery After Stroke.
TLDR
Improved insights into stroke recovery and its treatment have the potential to reduce disability in a large segment of stroke survivors. Expand
Pharmacological Enhancement of Stroke Recovery
TLDR
Various drugs, including modulators of neurotransmitters, axonal growth inhibitor blockers, and growth factors, have been examined in preclinical and clinical studies for their ability to promote neural repair, particularly in the motor system. Expand
Monoclonal antibody as an emerging therapy for acute ischemic stroke.
TLDR
This review will focus on recent advances on AIS therapy by using mAb that targets the signaling cascades and endogenous molecules such as inflammation, growth factors, acid-sensing ion channels, and N-methyl-D-aspartate receptors. Expand
Safety and efficacy of recovery-promoting drugs for motor function after stroke: A systematic review of randomized controlled trials.
TLDR
Candidate drug interventions promoting motor recovery post-stroke were identified, specifically selective serotonin reuptake inhibitors and levodopa; however, the high risk of bias in many trials is concerning. Expand
New directions in treatment of the ischemic stroke
TLDR
New methods including fluoxetine, aripiprazole, L-DOPA, cholinergic and noradrenergic drugs, growth factors, monoclonal antibodies, allogenic stem cells, neurostimulators, robotic therapy and telerehabilitation are reviewed, which give hope for curing a larger number of patients and improving effects of rehabilitation after ischemic stroke. Expand
Enhancing Plasticity of the Central Nervous System: Drugs, Stem Cell Therapy, and Neuro-Implants
TLDR
A review of novel drug therapies with strong potential in the clinic for functional recovery after stroke and new avenues of stem cell therapy in patients with a cerebral lesion are discussed. Expand
New Directions in Treatments Targeting Stroke Recovery.
TLDR
A number of promising research directions have been identified for treatments targeting stroke recovery and their readiness for incorporation into clinical practice based on synthesis of current evidence is identified. Expand
Advances in Stroke 2017
TLDR
It is found that concentrations of FABP4 (fatty acid–binding protein 4), an intracellular lipid chaperone involved in coordination of lipid transportation and atherogenesis, were a novel independent prognostic marker for poor functional outcome and mortality 3 months poststroke. Expand
Treatments to Promote Neural Repair after Stroke
TLDR
Therapies based on neural repair hold the promise of providing additional treatment options to a majority of patients with stroke and have a treatment time window measured in days, weeks, or longer. Expand
Predictive Value of Upper Extremity Outcome Measures After Stroke—A Systematic Review and Metaregression Analysis
TLDR
Which assessments are common in large-scale, longitudinal stroke trials and how these quantify the change in upper limb function from stroke onset up to 1 year are described. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 55 REFERENCES
Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Repeat Doses of GSK249320 in Patients With Stroke
TLDR
Modality-specific end points could be consistently measured in the first few days after stroke, and one of these, gait velocity, demonstrated a trend toward improvement with GSK249320 compared with placebo, suggesting that this first study of a monoclonal antibody to modulate the neurobiology of brain repair after stroke was generally well tolerated. Expand
GSK249320, A Monoclonal Antibody Against the Axon Outgrowth Inhibition Molecule Myelin-Associated Glycoprotein, Improves Outcome of Rodents with Experimental Stroke
TLDR
The data suggest that intravenous GSK249320 penetrates the lesion site and is associated with a small effect on functional outcomes when initiated 24 hours post-stroke and so support the translational potential of this monoclonal antibody as a restorative therapy for patients with stroke. Expand
First‐Time‐in‐Human Study With GSK249320, a Myelin‐Associated Glycoprotein Inhibitor, in Healthy Volunteers
TLDR
GSK249320, a monoclonal antibody directed against myelin‐associated glycoprotein (MAG), is being developed for the enhancement of recovery of function poststroke and was well tolerated at all doses, with AUC showing dose linearity. Expand
Effects of Postinfarct Myelin-Associated Glycoprotein Antibody Treatment on Motor Recovery and Motor Map Plasticity in Squirrel Monkeys
TLDR
Results suggest that GSK249320 has a substantial biological effect on spared cortical tissue, however, its mechanisms of action may be widespread and not strictly limited to peri-infarct cortex and nearby premotor areas. Expand
Identification of Neuroprotective Properties of Anti-MAG Antibody: A Novel Approach for the Treatment of Stroke?
  • E. Irving, M. Vinson, +9 authors A. A. Parsons
  • Medicine
  • Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism
  • 2005
TLDR
The novel finding that an anti-MAG monoclonal antibody not only possesses the ability to neutralise the inhibitory effect of MAG on neurons but also directly protects oligodendrocytes from glutamate-mediated oxidative stress-induced cell death is reported here. Expand
Drugs to Enhance Motor Recovery After Stroke
TLDR
Because restorative drugs aim to change brain structure and function, their effects are influenced by concomitant behavioral experience, a finding that informs selection of entry criteria, outcome measures, and biomarkers in a clinical trial setting underscores the importance of a neural systems approach in studying stroke recovery. Expand
Repairing the human brain after stroke. II. Restorative therapies
TLDR
Considerations for clinical trials of restorative therapies are provided, emphasizing both similarities and points of divergence with acute stroke clinical trial design. Expand
Update of the Stroke Therapy Academic Industry Roundtable Preclinical Recommendations
TLDR
The updated STAIR preclinical recommendations reinforce the previous suggestions that reproducibly defining dose response and time windows with both histological and functional outcomes in multiple animal species with appropriate physiological monitoring is appropriate. Expand
Clinical issues in animal models of stroke and rehabilitation.
TLDR
Evidence in human studies increasingly suggests that high levels of physiotherapy after stroke may be associated with improved clinical outcome, and several new therapeutic approaches are described herein. Expand
Antibodies to myelin‐associated glycoprotein accelerate preferential motor reinnervation
TLDR
Antibody administration has a generalized effect on sensory regeneration that is unrelated to the behavior of motoneurons in the same nerve, and blocking access to MAG in the distal nerve stump thus accelerated and enhanced PMR. Expand
...
1
2
3
4
5
...